BiotechTube
Home/BridgeBio Oncology Therapeutics/Andrew Lo
AL

Andrew Lo

COO of BridgeBio Pharma (Parent Company Oversight)

BridgeBio Oncology Therapeutics

Therapeutic Areas

OncologyPrecision Oncology

BridgeBio Oncology Therapeutics Pipeline

DrugIndicationPhase
Active-State RAS InhibitorSolid tumors with broad KRAS mutations (e.g., G12D, G12V)Preclinical / Early Clinical
RAS-Selective PI3Kα InhibitorRAS-mutant solid tumorsPreclinical / Early Clinical

Leadership Team at BridgeBio Oncology Therapeutics

NK
Neil Kumar
Founder & CEO of BridgeBio Pharma (Parent Company Oversight)
BS
Brian Stephenson
CFO of BridgeBio Pharma (Parent Company Oversight)
View full BridgeBio Oncology Therapeutics profile